Log In
BCIQ
Print this Print this
 

ravidasvir (ASC16, PPI-668)

  Manage Alerts
Collapse Summary General Information
Company Presidio Pharmaceuticals Inc.
DescriptionSecond-generation HCV NS5A protein inhibitor
Molecular Target HCV NS5A protein
Mechanism of ActionHCV non-structural protein 5A inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationHepatitis C virus (HCV)
Indication DetailsTreat chronic HCV genotype 1 infection in treatment-naïve patients; Treat chronic HCV genotype 4 infection; Treat HCV genotype 1 infection
Regulatory Designation
PartnerAscletis Pharmaceuticals Co. Ltd.;
Pharco Corp.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

3

$100.7M

$100.7M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today